Core Viewpoint - Shenwei Pharmaceutical (02877) has shown significant stock performance, rising over 3% to HKD 8.51, with a trading volume of HKD 10.48 million, indicating positive market sentiment towards the company [1] Group 1: Company Research and Development - Guoyuan International's report highlights Shenwei Pharmaceutical's notable achievements in traditional Chinese medicine innovation, with multiple research and clinical projects progressing smoothly [1] - The company's R&D expenses for the first half of 2025 amounted to RMB 50.37 million, representing 3.0% of its revenue [1] - Key products under development, such as Q-B-Q-F Concentrated Pills and Selotong Capsules, are advancing steadily, with Selotong Capsules having completed Phase III clinical trials [1] Group 2: Market Potential and Product Overview - Selotong Capsules, developed using modern innovative technology, target vascular dementia, which is the second most common cause of dementia after Alzheimer's disease [1] - It is projected that by 2025, the number of elderly dementia patients in China will exceed 10 million, with no effective treatment drugs currently available, indicating a vast market opportunity for Selotong Capsules [1] - The product is expected to receive production approval in 2026 and be launched in 2027, positioning it as a significant future product for the company [1]
港股异动 | 神威药业(02877)涨超3% 塞络通胶囊已经完成III期临床试验 预计明年有望...